S. 1096 119th Congress
Preserve Access to Affordable Generics and Biosimilars Act
- Health
- Sponsor: Sen. Klobuchar, Amy [D-MN]
- Congress.gov ↗
Latest action, Apr 10, 2025: Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
How the House voted
The House hasn't taken a roll call on this bill in the Congresses covered.
8 cosponsors
Sponsored by Sen. Klobuchar, Amy [D-MN] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
5 D · 3 R
- Democrat
- Republican
- Independent
Referred to: Senate: Judiciary Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
THE GIBSON GROUP, LLC
7 reports
BCBSM INC
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
CROSSROADS STRATEGIES, LLC
7 reports
TEVA PHARMACEUTICALS USA, INC.
FAEGRE DRINKER BIDDLE & REATH LLP
7 reports
The top 25 of 40 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 7 | $28.6M | Q1 2025 | Q3 2026 | yes | |
| AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA) | 7 | $70K | Q1 2025 | Q3 2026 | yes | |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 7 | $5.6M | Q1 2025 | Q3 2026 | yes | |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | THE GIBSON GROUP, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| BCBSM INC | 7 | $206K | Q1 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 7 | $8.8M | Q1 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 7 | $810K | Q1 2025 | Q3 2026 | yes | |
| BLUE CROSS BLUE SHIELD OF MICHIGAN | 7 | $1.9M | Q1 2025 | Q3 2026 | yes | |
| CAMBIA HEALTH SOLUTIONS | 7 | $4.6M | Q1 2025 | Q3 2026 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.9M | Q1 2025 | Q3 2026 | yes | |
| GUIDEWELL MUTUAL HOLDING CORPORATION | 7 | $40K | Q1 2025 | Q3 2026 | yes | |
| NOVARTIS | 7 | $14.0M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $64.5M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | CROSSROADS STRATEGIES, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| TEVA PHARMACEUTICALS USA, INC. | FAEGRE DRINKER BIDDLE & REATH LLP | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 7 | $630K | Q1 2025 | Q3 2026 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 6 | $10.3M | Q1 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD OF KANSAS INC | 6 | $60K | Q1 2025 | Q3 2026 | yes | |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | WHITMER & WORRALL, LLC | 6 | $300K | Q1 2025 | Q2 2026 | yes |
| TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) | TIBER CREEK GROUP | 6 | $480K | Q4 2025 | Q3 2026 | — |
| VIATRIS (MYLAN, INC) | S-3 GROUP | 6 | $360K | Q4 2025 | Q3 2026 | yes |
| CONSERVATIVES FOR PROPERTY RIGHTS | ELITE STRATEGIC SERVICES | 4 | $163K | Q4 2025 | Q1 2026 | yes |
| T1INTERNATIONAL USA | 4 | $0 | Q1 2025 | Q1 2026 | yes | |
| AARP | 3 | $15.6M | Q1 2025 | Q1 2026 | yes | |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | TWINLOGIC STRATEGIES, LLP | 3 | $0 | Q1 2026 | Q3 2026 | yes |